Clinical TrialsThe company has submitted an IND with the FDA to expand the ATALANTA trial to the U.S., indicating potential growth in new markets.
Research And DevelopmentGalapagos is advancing multiple Phase I/II CAR T programs in oncologic indications, with early data showing promising efficacy and clean safety profiles.
Strategic CollaborationsThe company has entered into a strategic collaboration with Global Blood Therapeutics to further expand its CAR-T production system in the region.